Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Study: Anemia may increase risk of dementia

Study: Anemia may increase risk of dementia

CHOP researchers advance stem cell studies in childhood leukemia, Diamond Blackfan anemia

CHOP researchers advance stem cell studies in childhood leukemia, Diamond Blackfan anemia

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

EKF Diagnostics introduces STAT-Site M ß-HB strip test for DKA assessment

EKF Diagnostics introduces STAT-Site M ß-HB strip test for DKA assessment

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Researchers receive $10M March of Dimes grant to study causes of premature birth

Researchers receive $10M March of Dimes grant to study causes of premature birth

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

International team explores genetic diversity of Plasmodium vivax in the Americas

International team explores genetic diversity of Plasmodium vivax in the Americas

New noninvasive technique for tracking stem cells after transplantation

New noninvasive technique for tracking stem cells after transplantation

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Research shows over 50% of tumors have mutations in p53

Research shows over 50% of tumors have mutations in p53

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.